Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2005

View Archived Issues

NB-001 successfully completes phase II study in herpes labialis

CRADA for antiviral testing of Tarvacin

SC-236 attenuates colon tumor activity associated with cigarette smoking

First dual modulator of PGI2 and TXA2 shows promise as an antithrombotic agent

New class of intestinal Pi absorption inhibitor

Japanese Committee for Usage of Unapproved Drugs rules on Chugai drugs

Nonapprovable letter for Namenda for mild Alzheimer's disease

Vernalis completes acquisition of Ionix

Acambis' C. difficile vaccine begins phase I study

Phase III study of MyVax Personalized Immunotherapy cleared to continue

Tapestry to focus on development of TPI-287

U.K. phase I study of Reolysin begins enrollment

Ozarelix begins U.S. phase I/II trial for hormone-dependent prostate cancer

Adacel vaccine now available in U.S.

Novacea and Pierre Fabre partner on oral vinorelbine

Recent patents cover novel treatments for cognitive disorders

Trifunctional bispecific antibodies show promise in the treatment of cancer

Zegerid Chewable Tablets NDA accepted for filing

Blockade of melanocortin-4 receptors increases the potency of morphine

Novel anti-HIV agents reported by Panacos

NDA for indiplon tablets accepted for review

(-)-Gossypol induces apoptosis in cisplatin-resistant head and neck cancer cells

Salagen approved in Japan

Ruboxistaurin reduces vision loss risk in patients with diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...